PriceTargets.com logo

Zogenix - ZGNX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$26.68 As of 03/15/2022 01:00 AM ET
+0 (0.00%)
Get New Zogenix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ZGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ZGNX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Zogenix in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $26.68.

This chart shows the closing price for ZGNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Zogenix. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2022Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
1/19/2022JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
1/19/2022William BlairDowngradeOutperform ➝ Market PerformHigh
1/19/2022Needham & Company LLCDowngradeBuy ➝ HoldHigh
1/19/2022GuggenheimDowngradeBuy ➝ NeutralHigh
1/19/2022Northland SecuritiesLower Target$32.00 ➝ $26.00High
12/20/2021SVB LeerinkLower TargetOutperform$37.00 ➝ $32.00High
11/12/2021SVB LeerinkReiterated RatingBuy$37.00Medium
11/5/2021JMP SecuritiesReiterated RatingBuy$62.00High
10/28/2021Northland SecuritiesLower TargetOutperform$40.00 ➝ $32.00Low
9/9/2021UBS GroupInitiated CoverageBuy$23.00Low
8/6/2021Needham & Company LLCLower TargetBuy$48.00 ➝ $44.00High
8/6/2021SVB LeerinkLower TargetOutperform$42.00 ➝ $37.00High
8/6/2021CitigroupLower TargetNeutral$23.00 ➝ $20.00High
7/10/2021Raymond JamesSet Target$17.67Low
7/9/2021Raymond JamesReiterated RatingHoldLow
12/14/2020Needham & Company LLCReiterated RatingBuyHigh
12/2/2020MizuhoReiterated RatingBuy$64.00Low
11/10/2020MizuhoReiterated RatingBuy$55.00Medium
8/24/2020Raymond JamesInitiated CoverageMarket PerformLow
8/6/2020MizuhoReiterated RatingBuy$55.00Medium
8/6/2020Northland SecuritiesReiterated RatingBuy$65.00High
6/29/2020MizuhoLower Target$64.00 ➝ $55.00Low
6/26/2020Needham & Company LLCLower TargetBuy$50.00 ➝ $48.00Medium
6/26/2020Northland SecuritiesInitiated CoverageBuy$65.00Medium
6/26/2020William BlairReiterated RatingBuyMedium
5/6/2020Needham & Company LLCLower TargetBuy$54.00 ➝ $50.00Low
5/5/2020Piper SandlerLower TargetOverweight$64.00 ➝ $56.00Low
4/23/2020Northland SecuritiesReiterated RatingBuy$65.00High
4/1/2020MizuhoLower TargetBuy$71.00 ➝ $64.00High
3/5/2020CitigroupInitiated CoverageNeutral$27.00High
2/28/2020LADENBURG THALM/SH SHReiterated RatingHoldHigh
2/14/2020Stifel NicolausReiterated RatingBuyN/A
2/7/2020Needham & Company LLCReiterated RatingBuy$58.00 ➝ $54.00High
2/7/2020LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$60.00 ➝ $35.00High
1/21/2020GuggenheimReiterated RatingPositive ➝ Buy$64.00 ➝ $78.00Medium
12/10/2019Needham & Company LLCReiterated RatingBuy$58.00Low
12/10/2019MizuhoReiterated RatingBuy$65.00Low
12/6/2019Piper Sandler CompaniesReiterated RatingBuy$64.00Low
11/25/2019Northland SecuritiesReiterated RatingBuyHigh
10/21/2019MizuhoSet TargetBuy$65.00Medium
10/21/2019Needham & Company LLCInitiated CoverageBuy$58.00Low
9/26/2019JMP SecuritiesSet TargetBuy$69.00Medium
9/26/2019MizuhoReiterated RatingBuy$65.00Medium
9/5/2019MizuhoSet TargetBuy$65.00High
8/26/2019Northland SecuritiesSet TargetBuy$60.00Low
8/26/2019Piper Sandler CompaniesSet TargetBuy$64.00Low
8/26/2019William BlairReiterated RatingOutperformLow
8/7/2019Stifel NicolausSet TargetBuy$71.00High
7/8/2019Northland SecuritiesReiterated RatingBuy$60.00Low
6/28/2019MizuhoBoost TargetBuy ➝ Positive$58.00 ➝ $65.00Low
6/27/2019GuggenheimUpgradeNeutral ➝ Buy$40.00 ➝ $64.00Low
(Data available from 4/20/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/20/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Zogenix logo
Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.
Read More

Today's Range

Now: $26.68
Low: $26.68
High: $26.68

50 Day Range

MA: $26.52
Low: $26.10
High: $26.68

52 Week Range

Now: $26.68
Low: $11.03
High: $26.90

Volume

94 shs

Average Volume

3,764,363 shs

Market Capitalization

$1.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Zogenix?

The following equities research analysts have issued stock ratings on Zogenix in the last year: StockNews.com.
View the latest analyst ratings for ZGNX.

What is the current price target for Zogenix?

0 Wall Street analysts have set twelve-month price targets for Zogenix in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Zogenix in the next year.
View the latest price targets for ZGNX.

What is the current consensus analyst rating for Zogenix?

Zogenix currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ZGNX.

What other companies compete with Zogenix?

Other companies that are similar to Zogenix include Supernus Pharmaceuticals, Pacira BioSciences, ORIC Pharmaceuticals, Corcept Therapeutics and Stoke Therapeutics. Learn More about companies similar to Zogenix.

How do I contact Zogenix's investor relations team?

Zogenix's physical mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company's listed phone number is (510) 550-8300 and its investor relations email address is [email protected]. The official website for Zogenix is www.zogenix.com. Learn More about contacing Zogenix investor relations.